PMID- 25581596
OWN - NLM
STAT- MEDLINE
DCOM- 20150512
LR  - 20190221
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 100
IP  - 3
DP  - 2015 Mar
TI  - Postoperative simultaneous integrated boost-intensity modulated radiation therapy 
      for patients with locoregionally advanced papillary thyroid carcinoma: 
      preliminary results of a phase II trial and propensity score analysis.
PG  - 1009-17
LID - 10.1210/jc.2014-3242 [doi]
AB  - CONTEXT: With recent technical advances in radiotherapy (RT) planning, 
      simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT) has 
      made possible the delivery of high radiation dose to the tumor, minimizing 
      surrounding normal tissues. OBJECTIVE: This study aimed to evaluate the clinical 
      effectiveness and safety of postoperative SIB-IMRT in patients with 
      locoregionally advanced papillary thyroid cancer (PTC). DESIGN AND SETTING: This 
      was a propensity score-matched case control study conducted at a tertiary 
      referring center. PATIENTS OR OTHER PARTICIPANTS: This study included 
      locoregionally advanced patients with PTC (pT4 or N1b) who underwent thyroid 
      cancer surgery and radioactive iodine ablation (RIA) followed by postoperative 
      SIB-IMRT (RT group) under a phase II trial or no postoperative RT (Non-RT group) 
      Intervention: Postoperative SIB-IMRT was the intervention. MAIN OUTCOME MEASURES: 
      locoregional relapse-free survival (LRFS) was compared between RT group and 
      Non-RT group. RESULTS: Multivariate analysis showed that several factors, 
      including sex, American Thyroid Association risk category, and use of 
      postoperative RT were significantly associated with LRFS in all 201 patients (P < 
      .05 each). In the 118 propensity score-matched patients, there were no 
      significant differences in baseline characteristics between the RT and Non-RT 
      groups, but the LRFS rate was significantly higher in the RT than in the Non-RT 
      group (4 y: 100% vs 84.6%, P = .002). Overall, SIB-IMRT was well tolerated, with 
      no grade >/=3 toxicity, and was completed as planned in all patients. CONCLUSIONS: 
      Postoperative SIB-IMRT is feasible and effective in improving locoregional 
      control in patients with locally advanced PTC. Large-scale randomized studies are 
      warranted.
FAU - Lee, Eun Kyung
AU  - Lee EK
AD  - Center for Thyroid Cancer, Research Institute and Hospital (E.K.L., Y.J.L., Y.J., 
      J.R., T.H.K., C.Y.L., C.H.R., T.S.K., S.K.K., K.W.C., S.S.K., D.Y.K., J.Y.K., 
      K.H.C.), National Cancer Center, Goyang, 410-769, Republic of Korea; and 
      Department of Surgery (K.W.C.), Asan Medical Center, Seoul, 138-736, Rupublic of 
      Korea.
FAU - Lee, You Jin
AU  - Lee YJ
FAU - Jung, Yuh-S
AU  - Jung YS
FAU - Ryu, Junsun
AU  - Ryu J
FAU - Kim, Tae Hyun
AU  - Kim TH
FAU - Lee, Chang Yoon
AU  - Lee CY
FAU - Ryu, Chang Hwan
AU  - Ryu CH
FAU - Kim, Tae Sung
AU  - Kim TS
FAU - Kim, Seok Ki
AU  - Kim SK
FAU - Chung, Ki-Wook
AU  - Chung KW
FAU - Kim, Sang Soo
AU  - Kim SS
FAU - Kim, Dae Yong
AU  - Kim DY
FAU - Kim, Joo Young
AU  - Kim JY
FAU - Cho, Kwan Ho
AU  - Cho KH
LA  - eng
SI  - ClinicalTrials.gov/NCT01173289
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150112
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma/epidemiology/pathology/*radiotherapy/*surgery
MH  - Carcinoma, Papillary
MH  - Case-Control Studies
MH  - Combined Modality Therapy
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Postoperative Period
MH  - Propensity Score
MH  - *Radiotherapy, Intensity-Modulated
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Neoplasms/epidemiology/pathology/*radiotherapy/*surgery
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2015/01/13 06:00
MHDA- 2015/05/13 06:00
CRDT- 2015/01/13 06:00
PHST- 2015/01/13 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2015/05/13 06:00 [medline]
AID - 10.1210/jc.2014-3242 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2015 Mar;100(3):1009-17. doi: 10.1210/jc.2014-3242. Epub 
      2015 Jan 12.